Erin Geddis Cummings, Bradley Zebrack receive Cancer Nation’s 2026 Ellen L. Stovall Award - The Cancer Letter

Trump weighs—and abandons—an executive order that would give OMB veto power over NIH grants - The Cancer Letter

FDA grants Priority Review to perioperative IMFINZI + enfortumab vedotin for muscle-invasive bladder cancer - The Cancer Letter

HHS issues direct final rule to reduce reliance on animal testing - The Cancer Letter

PDS0101 + pembrolizumab in HPV16+ R/M head and neck cancer show anti-tumor activity, VERSATILE-002 phase II study finds - The Cancer Letter

How biology is reshaping breast cancer care - The Cancer Letter

Rutika Mehta named director of upper GI medical oncology at NYU - The Cancer Letter

When did stage 3B lung cancer become “early stage”? - The Cancer Letter

Tagrisso increased OS in early-stage EGFR-mutated lung cancer at eight year follow-up, ADAURA phase III trial finds - The Cancer Letter

The Directors: Two Gulf Coast cancer center directors on why NCI designation matters—and why they want it Lucio Miele and Raghu Kalluri: Science and technology have changed what an aspiring cancer center must accomplish - The Cancer Letter

UNM Comprehensive Cancer Center earns NCI redesignation - The Cancer Letter

Trump weighs—and abandons—an executive order that would give OMB veto power over NIH grants - The Cancer Letter

FDA approves Lyrfigtu for previously treated, unresectable, locally advanced or metastatic cholangiocarcinoma - The Cancer Letter

FDA approves belzutifan in combination with lenvatinib for advanced RCC with a clear cell component - The Cancer Letter

When did stage 3B lung cancer become “early stage”? - The Cancer Letter

At confirmation hearing, Heidi Overton sidesteps questions about FDA regulation of fruit-flavored vapes - The Cancer Letter

Trump weighs—and abandons—an executive order that would give OMB veto power over NIH grants - The Cancer Letter

The Directors: Two Gulf Coast cancer center directors on why NCI designation matters—and why they want it Lucio Miele and Raghu Kalluri: Science and technology have changed what an aspiring cancer center must accomplish - The Cancer Letter

The Directors: Two Gulf Coast cancer center directors on why NCI designation matters—and why they want it Lucio Miele and Raghu Kalluri: Science and technology have changed what an aspiring cancer center must accomplish - The Cancer Letter

Kalil Abdullah to lead Northwell’s brain tumor program - The Cancer Letter

Harold Freeman, a surgeon who championed health equity, dies at 93 Freeman, the father of patient navigation, served as president of ACS and chair of the President’s Cancer Panel - The Cancer Letter

Cancer biosimilars associated with lower costs for insurers and patients, UCLA study finds - The Cancer Letter

Letai shares weekly musings in NCI’s new “Tuesdays with Tony” series - The Cancer Letter

Edward Kaftan named associate director for administration and scientific affairs at Dartmouth - The Cancer Letter

Scientific progress can’t help people if they can’t access care This is a policy problem. And it is one we can change. - The Cancer Letter

The end of “more money, more people, more trials” Cancer centers are being asked to grow their portfolios on flat budgets. Headcount is the wrong answer. - The Cancer Letter

Cancer centers continue to face recurring drug shortages, NCCN survey finds - The Cancer Letter

EGFR mutation linked to dramatically increased lung cancer risk - The Cancer Letter

D. Neil Hayes to lead OSUCCC’s Institute for Precision Cancer Medicine - The Cancer Letter

As Medicaid work requirements loom, CMS guidance offers automatic exemptions for some cancer patients Caveat: The guidance is optional. Will states opt in? - The Cancer Letter

Letai takes a swipe at “ill-informed commentators,” as he lays out his scientific vision for NCI “To my knowledge, 100% of grants that clear my desk get funded” - The Cancer Letter

Senthil K. Muthuswamy named director of NCI’s Center for Cancer Research - The Cancer Letter

Scientific progress can’t help people if they can’t access care This is a policy problem. And it is one we can change. - The Cancer Letter

ASCO expresses support for functional precision medicine, rescinding past objections - The Cancer Letter

FDA approves imlunestrant + abemaciclib for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer - The Cancer Letter

U.S. cancer death rate declined 35% since 1991, AACR Cancer Progress Report finds - The Cancer Letter

Harold Freeman, a surgeon who championed health equity, dies at 93 Freeman, the father of patient navigation, served as president of ACS and chair of the President’s Cancer Panel - The Cancer Letter

FDA grants accelerated approval to sevabertinib for locally advanced or metastatic non-squamous NSCLC - The Cancer Letter

As Medicaid work requirements loom, CMS guidance offers automatic exemptions for some cancer patients Caveat: The guidance is optional. Will states opt in? - The Cancer Letter

The end of “more money, more people, more trials” Cancer centers are being asked to grow their portfolios on flat budgets. Headcount is the wrong answer. - The Cancer Letter

Kennedy overhauls “too woke” USPSTF with the appointment of eight members Critics say new members will politicize, commercialize the panel - The Cancer Letter

Scientific progress can’t help people if they can’t access care This is a policy problem. And it is one we can change. - The Cancer Letter

Letai takes a swipe at “ill-informed commentators,” as he lays out his scientific vision for NCI “To my knowledge, 100% of grants that clear my desk get funded” - The Cancer Letter